The Greater Cannabis Company, Inc. (GCAN) 10-K 14 Apr 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Apr. 14, 2020	Jun. 28, 2019
Document And Entity Information
Entity Registrant Name	Greater Cannabis Company, Inc.
Entity Central Index Key	0001695473
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		60,786,011
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash	$ 24,662	$ 59,891
Advance to supplier	28,000
Total current assets	52,662	59,891
OTHER ASSETS
Pharmedica Exclusive License Agreement (less accumulated amortization and impairment of $100,000 and $10,251, respectively)		89,749
Total assets	52,662	149,640
CURRENT LIABILITIES
Accounts payable	17,517	17,890
Accrued interest	20,619	5,312
Accrued salaries	98,000	85,000
Accrued royalties	50,000
Advance from customer	27,977
Loans payable to related parties	260,000	260,000
Notes payable to third parties (less debt discounts of $505,937 and $550, respectively)	399,318	64,914
Derivative liability	725,865	280,310
Total current liabilities and total liabilities	1,599,296	713,426
STOCKHOLDERS' (DEFICIENCY)
Common stock; 500,000,000 shares authorized, $.001 par value, as of December 31, 2019 and 2018, there are 39,301,323 and 31,880,969 shares outstanding, respectively	39,301	31,881
Additional paid-in capital	783,891	233,991
Accumulated deficit	(2,379,238)	(839,070)
Total stockholders' (deficiency)	(1,546,634)	(563,786)
Total liabilities and stockholders' (deficiency)	52,662	149,640
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock	9,412	9,412
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accumulated amortization and impairment	$ 100,000	$ 10,251
Debt discount	$ 505,937	$ 550
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ .001	$ .001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ .001	$ .001
Common stock, shares outstanding	39,301,323	31,880,969
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,411,998	9,411,998
Preferred stock, shares outstanding	9,411,998	9,411,998
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Product sales	$ 4,500
Gross profit on product transactions (Note I)		86,898
Consulting fees (related party $0 and $8,477, respectively)	2,620	8,477
Total revenue	7,120	95,375
Operating Expenses:
Cost of product sales	3,125
Minimum royalties expense	50,000
Officers compensation	204,000	185,593
Consulting fees paid to former Chief Executive Officer		50,000
Amortization of Pharmedica Exclusive License Agreement cost	20,000	10,251
Impairment charge-Pharmedica Exclusive License Agreement cost	69,749
Other operating expenses (including stock-based professional fees of $88,130 and $0, respectively)	185,569	40,450
Total operating expenses	532,443	286,294
Income (loss) from operations	(525,323)	(190,919)
Other income (expenses):
Income (expense) from derivative liability	(303,981)	(9,808)
Loss on conversion of notes payable	(320,025)	(592,907)
Interest income		5,903
Interest expense	(35,776)	(28,487)
Amortization of debt discounts	(463,490)	(22,852)
Total other income (expenses)	(1,123,272)	(648,151)
Income (loss) before provision for income taxes	(1,648,595)	(839,070)
Provision for income taxes
Net income (loss)	$ (1,648,595)	$ (839,070)
Basic and diluted income (loss) per common share	$ (.05)	$ (0.03)
Weighted average common shares outstanding-basic and diluted	34,980,133	29,964,950

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Consulting Fees related party	$ 0	$ 8,477
Stock based professional fees	$ 88,130	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Series A Preferred Stock [Member]
Beginning Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412				$ 9,412
Beginning Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998				9,411,998
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018						$ 9,412
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018, shares						9,411,998
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018, shares
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018, shares
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018, shares
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019, shares
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019, shares
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019, shares
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares
Issuance of common shares for professional services rendered
Issuance of common shares for professional services rendered, shares
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock, shares
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares
Net income (loss)
Ending Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412			$ 9,412	$ 9,412
Ending Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998			9,411,998	9,411,998
Series B Preferred Stock [Member]
Beginning Balance	$ 9,000	$ 9,000	$ 9,000
Beginning Balance, shares	9,000,000	9,000,000	9,000,000
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018, shares
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018, shares
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018, shares
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018, shares
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019, shares
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019, shares
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019				$ 9,000
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019, shares				9,000,000
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares
Issuance of common shares for professional services rendered
Issuance of common shares for professional services rendered, shares
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock	$ (9,000)
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock, shares	(9,000,000)
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares
Net income (loss)
Ending Balance		$ 9,000	$ 9,000	$ 9,000
Ending Balance, shares		9,000,000	9,000,000	9,000,000
Common Stock [Member]
Beginning Balance	$ 35,447	$ 35,272	$ 33,346	$ 31,881	$ 30,846				$ 31,881
Beginning Balance, shares	35,447,483	35,272,483	33,345,883	31,880,969	30,846,492	100	100	100	31,880,969	100
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018, shares						(100)
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018						$ 29,381
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018, shares						29,380,969
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018						$ 1,465
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018, shares						1,465,523
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018					$ 1,035
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018, shares					1,034,477
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019				$ 770
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019, shares				769,785
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019				$ 695
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019, shares				695,129
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019, shares
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019			$ 1,384
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares			1,384,600
Issuance of common shares for professional services rendered		$ 175	$ 542
Issuance of common shares for professional services rendered, shares		175,000	542,000
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock, shares
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019	$ 1,749
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares	1,748,363
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019	$ 1,468
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares	1,468,204
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019	$ 637
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares	637,273
Net income (loss)
Ending Balance	$ 39,301	$ 35,447	$ 35,272	$ 33,346	$ 31,881	$ 30,846			$ 39,301	$ 31,881
Ending Balance, shares	39,301,323	35,447,483	35,272,483	33,345,883	31,880,969	30,846,492	100	100	39,301,323	31,880,969
Additional Paid-In Capital [Member]
Beginning Balance	$ 589,625	$ 577,550	$ 323,598	$ 233,991	$ 121,234				$ 233,991
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018						(9,412)
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018						(414,676)
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018						545,322
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018					112,757
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019				99,302
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019				(695)
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019				(9,000)
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019			178,614
Issuance of common shares for professional services rendered		12,075	75,338
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock	9,000
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019	103,152
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019	57,260
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019	24,854
Net income (loss)
Ending Balance	783,891	589,625	577,550	323,598	233,991	121,234			783,891	233,991
Accumulated Deficit [Member]
Beginning Balance	(1,283,201)	(1,156,771)	(868,992)	(839,070)	(863,543)	100,779	78,465		(839,070)
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019				108,427
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Issuance of common shares for professional services rendered
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Net income (loss)	(1,096,037)	(126,430)	(287,779)	(138,349)	24,473	(964,322)	22,314	78,465
Ending Balance	(2,379,238)	(1,283,201)	(1,156,771)	(868,992)	(839,070)	(863,543)	100,779	78,465	(2,379,238)	(839,070)
Beginning Balance	(639,717)	(525,537)	(493,636)	(563,786)	(702,051)	100,779	78,465		(563,786)
Issuance of 9,411,988 shares of Series A convertible preferred stock in exchange for 100 shares of Green C Corporation common stock on July 31, 2018
Shares of The Greater Cannabis Company, Inc. ("GCAN") common stock retained by GCAN stockholders in connection with reverse acquisition of GCAN on July 31, 2018						(385,295)
Issuance of 1,465,523 shares of common stock from conversion of notes payable and accrued interest on September 19, 2018						546,787
Issuance of 1,034,477 shares of common stock from conversion of notes payable and accrued interest on October 26, 2018					113,792
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019				108,427
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019				100,072
Exercise of 1400 warrants into 645,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019			179,998
Issuance of common shares for professional services rendered		12,250	75,880
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019	104,901
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019	58,728
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019	25,491
Net income (loss)	(1,096,037)	(126,430)	(287,779)	(138,349)	24,473	(964,322)	22,314	78,465	(1,648,595)	(839,070)
Ending Balance	$ (1,546,634)	$ (639,717)	$ (525,537)	$ (493,636)	$ (563,786)	$ (702,051)	$ 100,779	$ 78,465	$ (1,546,634)	$ (563,786)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Parenthetical) - USD ($)	Jul. 31, 2018	Mar. 31, 2019
Common Stock [Member]
Number of preferred stock issued for common stock		769,785
Green C Corporation [Member]
Number of preferred stock issued for common stock	100
Series A Convertible Preferred Stock [Member]
Number of stock issued for conversion	9,411,988
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Issuance of common stock in cashless exercise transaction, shares	9,411,998
Conversion of convertible preferred stock	50

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
OPERATING ACTIVITIES
Net income (loss)	$ (1,648,595)	$ (839,070)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Loss on conversion of note payable and accrued interest to common stock	320,025	592,907
Issuance of stock-based professional fees	88,130
(Income) expense from derivative liability	303,981	9,808
Amortization of Pharmedica Exclusive License Agreement cost	20,000	10,251
Impairment charge- Pharmedica Exclusive License Agreement cost	69,749
Interest expense for default added to note payable balance		21,270
Amortization of debt discounts	463,490	22,852
Changes in operating assets and liabilities:
Advance to supplier	(28,000)
Accounts payable	(383)	74,676
Accrued interest	35,397	7,197
Accrued salaries	13,000
Accrued royalties	50,000
Advance from customer	27,977
Net cash used in operating activities	(285,229)	(100,109)
INVESTING ACTIVITIES
Loan to third party		(296,043)
Repayment of loan to third party		296,043
Net cash used in investing activities
FINANCING ACTIVITIES
Proceeds from loan payable to related party		783
Repayment of loan payable to related party		(783)
Proceeds from loans payable to related parties		160,000
Proceeds from notes payable to third parties	250,000
Net cash provided by financing activities	250,000	160,000
NET INCREASE (DECREASE) IN CASH	(35,229)	59,891
CASH BALANCE, BEGINNING OF PERIOD	59,891
CASH BALANCE, END OF PERIOD	24,662	59,891
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income tax paid
Non-cash Investing and Financing Activities:
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 2019	100,072
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019	695
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019. Exchange Agreement reversed on October 18, 2019
Initial derivative liability charged to debt discount	250,000
Conversion of note payable ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (fair value of $179,998) on April 16, 2019	179,998
Payment from related party to licensor of Pharmedica Exclusive License Agreement on June 26, 2018		100,000
Liabilities of The Greater Cannabis Company, Inc. at July 31, 2018 added pursuant to reverse acquisition:
Accounts payable and accrued expenses		28,214
Accrued interest		2,123
Notes payable to third parties		83,323
Derivative liability		270,502
Total		385,295
Conversion of notes payable and accrued interest to 2,500,000 shares of common stock
Accrued interest		5,141
Notes payable to third parties		62,531
Total		67,672
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019	104,901
Conversion of note payables ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019	58,728
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $25,491) on December 24, 2019	$ 25,491

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Feb. 14, 2019	Jan. 04, 2019
Conversion of note payable	$ 10,000	$ 29,000	$ 53,705	$ 40,500		$ 670
Accrued interest	$ 515	$ 4,035	$ 2,680	$ 7,961		$ 100
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600		769,785
Debt conversion of shares, value	$ 58,728	$ 58,728	$ 104,901	$ 100,072		$ 100,072
Exercise of warrants						1,400
Issuance of common stock in cashless exercise transaction, shares						645,129
Exchange of warrants					438,600
Class B Convertible Preferred Stock [Member]
Conversion of convertible preferred stock					9,000,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. See Note C (Acquisition of Green C Corporation). Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with the principle place of business in North York, Ontario. Green C is the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. The Company is actively seeking licensing opportunities in the cannabis sector for intellectual property and products. At present, the Company’s sole active, exclusive, worldwide licensing agreement is with Pharmedica Limited for its ETP technology. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Green C Corporation. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2019, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Pharmedica Exclusive License Agreement cost The Pharmedica Exclusive License Agreement is carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the license’s estimated economic life of five years. (see Note J) Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. Revenue Recognition Revenue from product sales will be recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note G), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presentd. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative affect adjustment reduction of accumulated deficit. See Note F.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of December 31, 2019, the Company had cash of $24,662, total current liabilities of $1,599,296, and negative working capital of $1,546,634. For the year ended December 31, 2019, we incurred a net loss of $1,648,490 and used $285,229 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through March 2021. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

Acquisition of Green C Corporat

Acquisition of Green C Corporation	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Acquisition of Green C Corporation	NOTE C - ACQUISITION OF GREEN C CORPORATION As discussed in Note A above, the Company acquired 100% ownership of Green C Corporation on July 31, 2018. The acquisition has been accounted for in the accompanying consolidated financial statements as a “reverse acquisition” transaction. Accordingly, the financial position and results of operations of the Company prior to July 31, 2018 has been excluded from the accompanying consolidated financial statements. The carrying values of the net assets (liabilities) of the Company (The Greater Cannabis Company, Inc., and subsidiaries) at July 31, 2018 prior to the acquisition consisted of: Total Assets $ - Accounts payable and accrued expenses $ 90,724 Accrued interest 15,813 Loans payable to related parties 89,774 Notes payable to third parties 83,323 Derivative liability 270,502 Total current liabilities and total liabilities $ 550,136 Pursuant to terms of the acquisition agreements, $164,841 (accounts payable and accrued expenses - $62,500, accrued interest - $12,567, and loans payable to related parties - $89,774) of the $550,136 total liabilities was forgiven.

Loans Payable to Related Partie

Loans Payable to Related Parties	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Loans Payable to Related Parties	NOTE D - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: December 31, 2019 December 31, 2018 Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000 Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loan, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request.

Notes Payable to Third Parties

Notes Payable to Third Parties	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable to Third Parties	NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: December 31, 2019 December 31, 2018 Convertible Promissory Note dated May 25, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due May 25, 2018 (i) $ - $ 3,469 Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (ii) - 16,500 Convertible Promissory Note dated January 9, 2018 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due January 9, 2019-less unamortized debt discount of $0 and $550, respectively (iii) - 23,450 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (iv) 2,420 14,520 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (v) 1,100 6,600 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Convertible Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $33,396 and $0, respectively (vi) 250,082 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $294,234 and $0, respectively (vi) 74,566 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $90,0543 and $0, respectively (vii) 22,823 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $79,248 and $0, respectively (vii) 20,084 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $9,005 and $0, respectively (vii) 2,281 - Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (vii) 25,587 Total $ 399,318 $ 64,914 (i) On May 25, 2017, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $55,000 in exchange for $50,000 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (May 25, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 440,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. As part of the Convertible Note, the Company executed a Registration Rights Agreement (the “RRA”) dated May 25, 2017. Among other things, the RRA provided for the Company to file a Registration Statement with the SEC covering the resale of shares underlying the Convertible Note and the warrant and to have declared effective such Registration Statement. The Registration Statement was declared effective by the Securities and Exchange Commission on August 31, 2017. On September 19, 2018, $32,000 principal of the Convertible Note (and $4,638 accrued interest) was converted into 1,465,523 shares of Company common stock. On October 26, 2018, $30,531 principal of the Convertible Note (and $503 accrued interest) was converted into 1,034,477 shares of Company common stock. On January 4, 2019, $670 principal of the Convertible Note (and $100 accrued interest) was converted into 769,785 shares of Company common stock. Please see NOTE F - DERIVATIVE LIABILITY (ii) On September 14, 2017, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $13,750 in exchange for $12,500 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (September 14, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 110,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY (iii) On January 9, 2018, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $20,000 in exchange for entry into a Waiver Agreement pertaining to the Securities Purchase Agreements entered into between the Parties dated May 25, 2017 and September 14, 2017 along with a Convertible Note issued by the Company on each of the same dates. The Company received $0 cash from issuance of the Convertible Note. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (January 9, 2019) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). Please see NOTE F - DERIVATIVE LIABILITY (iv) On March 28, 2018, the Company made an Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the “Allonge”) to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $25,850 ($13,750 – original Principal Amount of the Debenture + $12,100 Allonge). The amendment to the Principal Amount due and owing on the Debenture described herein notwithstanding, the Holder does not waive interest that may have accrued at a default rate of interest and liquidated damages, if any, that may have accrued on the Debenture through the date of this Allonge, which default interest and liquidated damages, if any, remain outstanding and payable. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 98,600 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY (v) On September 13, 2018, the Company made a second Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the “Allonge”) to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $31,350 ($13,750 – original Principal Amount of the Debenture + $12,100 1 st nd see NOTE F - DERIVATIVE LIABILITY (vi) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. The Eagle Note will mature on one year from the Issue Date. Eagle is to fund the $1,104,000 purchase price of he Eagle Note in tranches. The first tranche of $250,000 was received by the Company on February 13, 2019. (vii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY The Eagle Note may be pre-paid in whole or in part by paying Eagle the following premiums: PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I) Any amount of principal or interest on the Eagle Note, which is not paid when due shall bear interest at the rate of twenty four (24%) per annum from the due date thereof until the same is paid (“Default Interest”). Eagle has the right beginning on the date which is one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the Eagle Note into fully paid and non-assessable shares of common stock of the Company at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 65% of the lowest closing price of the Company’s common stock as reported on the National Quotations Bureau OTC Market exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future (“Exchange”), for the fifteen prior trading days including the day upon which a Notice of Conversion is received by the Company. The Eagle Note contains other customary terms found in like instruments for conversion price adjustments. In the case of an Event of Default (as defined in the Eagle Note), the Eagle Note shall become immediately due and payable and interest shall accrue at the rate of Default Interest. Certain events of default will result in further penalties.

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	NOTE F - DERIVATIVE LIABILITY The derivative liability consists of: December 31, 2019 December 31, 2018 Convertible Promissory Note dated May 25, 2017 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information $ - $ 8,385 Warrants issued to EMET in connection with the above Convertible Promissory Note dated May 25, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 72,468 Convertible Promissory Note dated September 14, 2017 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 43,780 Warrants issued to EMET in connection with the above Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 18,150 Convertible Promissory Note dated January 9, 2018 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 63,680 Allonge dated March 28, 2018 to the Convertible Promissory Note dated September 14, 2017 Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 38,526 Warrants issued to EMET in connection with the above Allonge dated March 28, 2018 to the Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 15,991 Allonge 2 dated September 13, 2018 to the Convertible Promissory Note dated September 14, 2017 Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 17,512 Warrants issued to EMET in connection with the above Allonge 2 dated September 13, 2018 to the Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 1,818 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information 182,625 - Convertible Promissory Notes dated October 18, 2019, payable to EMET. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information 543,240 - Total derivative liability $ 725,865 $ 280,310 (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019. The Convertible Promissory Notes (the “Notes”) and the warrants contain obligations to reduce the conversion price of the Notes and the exercise price of the Warrants in the event that the Company sells, grants or issues any non-excluded shares, options, warrants or any convertible instrument at a price below the conversion price of the Notes and the exercise price of the Warrants (“ratchet-down” provisions). The Notes also contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes and exercise of the Warrants is indeterminate. The fair value of the derivative liability was measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at September 30, 2019 were (1) stock price of $0.1007 per share, (2) conversion prices ranging from $0.045 to $.0655 per share, (3) terms ranging from 135 days to 6 months, (4) expected volatility of 130.68%, and (5) risk free interest rates ranging from 1.83% to 1.85%. Assumptions used for the calculation of the derivative liability of the notes at December 31, 2018 were (1) stock price of $0.1655 per share, (2) conversion price of $0.0525 per share, (3) terms ranging from 3 months to 6 months, (4) expected volatility of 286.71%, and (5) risk free interest rates ranging from 2.47% to 2.50%.

Capital Stock and Warrants

Capital Stock and Warrants	12 Months Ended
	Dec. 31, 2019
Capital Stock And Warrants
Capital Stock and Warrants	NOTE G - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock. On February 14, 2019, the Company issued 9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. Each share of Series B Convertible Preferred Stock is convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock is less than $0.075 per share. On October 18, 2019, this exchange agreement was reversed. Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing 19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing 80.01% of the issued and outstanding shares of Company common stock after the spin-off). Effective March 22, 2017, the Company issued 100,000 shares of its common stock to a consulting firm entity for service rendered. The $25,000 estimated fair value of the 100,000 shares was expensed as consulting fees in the three months ended March 31, 2017. Effective March 31, 2017, the Company issued 2,000,000 shares of its common stock to our Chief Executive Officer, Wayne Anderson, for services rendered. The $500,000 estimated fair value of the 2,000,000 shares was expensed as officer compensation in the three months ended March 31, 2017. Effective September 15, 2017, the Company issued 375,000 shares of its common stock to retire a Note Payable to a Third Party. On September 19, 2018, the Company issued 1,465,523 shares of its common stock pursuant to a conversion of $32,000 principal and $4,638 accrued interest of its convertible note dated May 25, 2017 by Emet Capital Partners, LLC. The $510,149 excess of the $546,787 fair value of the 1,465,523 shares over the $36,638 liability reduction was charged to Loss on Conversion of Debt. On October 26, 2018, the Company issued 1,034,477 shares of its common stock pursuant to a conversion of $30,531 principal and $503 accrued interest of its convertible note dated May 25, 2017 by Emet Capital Partners, LLC. The $82,758 excess of the $113,792 fair value of the 1,034,479 shares over the $31,034 liability reduction was charged to Loss on Conversion of Debt. On January 4, 2019, the Company issued 769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The Company has notified Emet that it disagrees with Emet’s assertion that a ratch-down dilutive issuance occurred. The $99,302 excess of the $100,072 fair value of the 769,785 shares over the $770 liability reduction was charged to Loss on Conversion of Debt in the three months ended March 31, 2019. On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $0.001 per share. On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $40,500 principal and $7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019. On May 29, 2019, the Company issued a total of 542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019. On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses. On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. Warrants On May 25, 2017, the Company issued Emet Capital Partners, LLC a warrant granting the holder the right to purchase 440,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. If at any time after the Initial Exercise Date, there is no effective registration statement registering the Warrant Shares, or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at the Holder’s election, in whole or in part, at such time by means of a “cashless exercise”. The Holder of the warrant did not require that the Company register the common shares to be issued under the warrant in the Registration Statement declared effective August 31, 2017. (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES On September 14, 2017, the Company issued Emet Capital Partners, LLC a warrant granting the holder the right to purchase 110,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. If at any time after the Initial Exercise Date, there is no effective registration statement registering the Warrant Shares, or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at the Holder’s election, in whole or in part, at such time by means of a “cashless exercise”. The Holder of the warrant did not require that the Company register the common shares to be issued under the warrant in the Registration Statement declared effective August 31, 2017. (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES On March 28, 2018, the Company issued Emet Capital Partners, LLC a warrant granting the holder the right to purchase 96,800 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. If at any time after the Initial Exercise Date, there is no effective registration statement registering the Warrant Shares, or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at the Holder’s election, in whole or in part, at such time by means of a “cashless exercise”. The Holder of the warrant has not requested that the Company register the common shares to be issued under the warrant. (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES On June 13, 2018, the Company issued Emet Capital Partners, LLC a warrant granting the holder the right to purchase 11,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. If at any time after the Initial Exercise Date, there is no effective registration statement registering the Warrant Shares, or no current prospectus available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at the Holder’s election, in whole or in part, at such time by means of a “cashless exercise”. The Holder of the warrant has not requested that the Company register the common shares to be issued under the warrant. (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES Emet Warrant Restructuring On February 14, 2019, the Company entered into an exchange agreement with Emet Capital Partners, LLC (“Emet”) pursuant to which the Company issued Emet 9,000,000 shares of its Series B Convertible Preferred Stock (the “Series B Preferred Shares”) in exchange for the surrender of all outstanding warrants held by Emet. Each Series B Preferred Share was convertible into one share of the Company’s common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company’s common stock was less than $0.075. In such case, Emet was to receive an additional number of shares of common stock equal to the number of shares being converted divided by the applicable market price. On October 18, 2019, this exchange agreement was reversed. At December 31, 2019, the Company has no outstanding warrants.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE H - INCOME TAXES The Company and its United States subsidiaries expect to file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, will file Canada and Ontario income tax returns. At December 31, 2019 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is not more likely than not that the benefits will be realized. Due to significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

Gross Profit on Product Transac

Gross Profit on Product Transactions	12 Months Ended
	Dec. 31, 2019
Gross Profit On Product Transactions
Gross Profit on Product Transactions	NOTE I- GROSS PROFIT ON PRODUCT TRANSACTIONS In February 2018, Green C sold certain bitcoin mining rig machines to a North Carolina based third party entity for $2,929,000. Also in February 2018, Green C sold additional bitcoin mining rig machines to another North Carolina based third party entity for $1,720,000. The Company’s supplier of the products in these two transactions was Focus Global Supply (“FGS”), a business entity controlled by Elisha Kalfa, Green C’s Chief Executive Officer. Green C paid FGS total of $4,517,000 for these machines. Net of a total of $59,000 commission paid to a third party finder, Green C recognized a gross profit of $72,912 from these two sales. In June 2018, Green C sold certain telecommunications parts to a China based third party entity for a total of $111,147. Green C’s supplier of the products in these transactions was an Italy based third part entity which was paid $111,127 for these products. Including $13,965 commissions received from NFW Marketing, Inc., an entity affiliated with Elisha Kalfa, Green C’s Chief Executive Officer. Green C recognized a gross profit of $13,986 from this transaction.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE J - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of 5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so. The Company has generated only minimal revenues from this asset to date and has not paid the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0. Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10% to 17% of Symtomax sales of eluting patches developed from Company technology. The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year. Service Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”) and its newly appointed Chief Legal Officer (the “CLO”), for terms of five years. The Agreements provide for a monthly base salary of $10,000 for the CEO and a monthly base salary of $7,000 for the CLO. For the years ended December 31, 2019 and 2018, the Company expensed a total of $204,000 and $134,593, respectively, as officers compensation pursuant to these agreements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE K – SUBSEQUENT EVENTS During the first calendar quarter of 2020, we issued 21,484,688 shares of our common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The fair value of the shares issued aggregate $406,093 and has a conversion loss of $ 228,949. On January 27, 2020, the Company executed a Securities Purchase Agreement with GW Holdings, LLC, a New York limited liability company with its address at 137 Montague Street, Suite 291, Brooklyn, NY 11201. For value received, the Company issued a 6% convertible redeemable promissory note in the amount of $ 166,500 wit a maturity date of January 27, 2021. This note was issued with a $13,500 original issue discount such that the issuance price was $153,000. An amendment to a Securities Purchase Agreement entered into between the Company and Eagle Equities, LLC on February 12, 2019, was executed on January 27, 2020. A subsequent closing of an additional $150,000 in net proceeds to the Company note occurred on the filing of the Company’s resale registration statement covering the $1,200,000 note being purchased. An additional closing of $85,000 in net proceeds to the Company occurred on the effectiveness of such registration statement, provided that the shares registered under the registration statement are sufficient to allow for the full conversion of the funded portion of the Note into registered shares. The Buyer retains the right to purchase the unfunded balance of the $1,200,000 Note (the “Unfunded Balance”) until February 12, 2021, provided that each purchase must be in an amount of not less than $100,000. Any rights to purchase a portion of the Unfunded Balance outstanding after 12 months shall be terminated and the Buyer shall have no rights to purchase the Unfunded Balance. The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties. In addition, the Company agrees to reserve with its transfer agent, 400% of the discount value of the funded balance of the Note at each closing. All other terms and conditions of the SPA shall remain in full force and effect, unless modified by this Amendment. This amendment shall be governed and construed under the laws of the State of New York, without regard to its conflict of laws provision.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. See Note C (Acquisition of Green C Corporation). Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with the principle place of business in North York, Ontario. Green C is the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. The Company is actively seeking licensing opportunities in the cannabis sector for intellectual property and products. At present, the Company’s sole active, exclusive, worldwide licensing agreement is with Pharmedica Limited for its ETP technology.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiary Green C Corporation.
Cash and Cash Equivalents	Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents.
Income Taxes	Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2019, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments and Fair Value of Financial Instruments	Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.
Derivative Liabilities	Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Long-lived Assets	Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Pharmedica Exclusive License Agreement Cost	Pharmedica Exclusive License Agreement cost The Pharmedica Exclusive License Agreement is carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the license’s estimated economic life of five years. (see Note J)
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.
Related Parties	Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.
Revenue Recognition	Revenue Recognition Revenue from product sales will be recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.
Loss Per Share	Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note G), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS
Recently Enacted Accounting Standards	Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presentd. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative affect adjustment reduction of accumulated deficit. See Note F.

Acquisition of Green C Corpor_2

Acquisition of Green C Corporation (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The carrying values of the net assets (liabilities) of the Company (The Greater Cannabis Company, Inc., and subsidiaries) at July 31, 2018 prior to the acquisition consisted of: Total Assets $ - Accounts payable and accrued expenses $ 90,724 Accrued interest 15,813 Loans payable to related parties 89,774 Notes payable to third parties 83,323 Derivative liability 270,502 Total current liabilities and total liabilities $ 550,136

Loans Payable to Related Part_2

Loans Payable to Related Parties (Tables)	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Schedule of Loans Payable to Related Parties	Loans payable to related parties consist of: December 31, 2019 December 31, 2018 Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000

Notes Payable to Third Parties

Notes Payable to Third Parties (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Notes Payable to Third Parties	NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: December 31, 2019 December 31, 2018 Convertible Promissory Note dated May 25, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due May 25, 2018 (i) $ - $ 3,469 Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (ii) - 16,500 Convertible Promissory Note dated January 9, 2018 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due January 9, 2019-less unamortized debt discount of $0 and $550, respectively (iii) - 23,450 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (iv) 2,420 14,520 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 (v) 1,100 6,600 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Convertible Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $33,396 and $0, respectively (vi) 250,082 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $294,234 and $0, respectively (vi) 74,566 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $90,0543 and $0, respectively (vii) 22,823 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $79,248 and $0, respectively (vii) 20,084 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $9,005 and $0, respectively (vii) 2,281 - Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (vii) 25,587 Total $ 399,318 $ 64,914 (i) On May 25, 2017, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $55,000 in exchange for $50,000 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (May 25, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 440,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. As part of the Convertible Note, the Company executed a Registration Rights Agreement (the “RRA”) dated May 25, 2017. Among other things, the RRA provided for the Company to file a Registration Statement with the SEC covering the resale of shares underlying the Convertible Note and the warrant and to have declared effective such Registration Statement. The Registration Statement was declared effective by the Securities and Exchange Commission on August 31, 2017. On September 19, 2018, $32,000 principal of the Convertible Note (and $4,638 accrued interest) was converted into 1,465,523 shares of Company common stock. On October 26, 2018, $30,531 principal of the Convertible Note (and $503 accrued interest) was converted into 1,034,477 shares of Company common stock. On January 4, 2019, $670 principal of the Convertible Note (and $100 accrued interest) was converted into 769,785 shares of Company common stock. Please see NOTE F - DERIVATIVE LIABILITY (ii) On September 14, 2017, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $13,750 in exchange for $12,500 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (September 14, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 110,000 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY (iii) On January 9, 2018, the Company executed a Convertible Note (the “Convertible Note”) payable to Emet Capital Partners, LLC, (“EMET”) in the principal amount of $20,000 in exchange for entry into a Waiver Agreement pertaining to the Securities Purchase Agreements entered into between the Parties dated May 25, 2017 and September 14, 2017 along with a Convertible Note issued by the Company on each of the same dates. The Company received $0 cash from issuance of the Convertible Note. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (January 9, 2019) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the “Fixed Conversion Price”); or (ii) 50% multiplied by the Market Price (as defined). “Market Price” means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). Please see NOTE F - DERIVATIVE LIABILITY (iv) On March 28, 2018, the Company made an Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the “Allonge”) to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $25,850 ($13,750 – original Principal Amount of the Debenture + $12,100 Allonge). The amendment to the Principal Amount due and owing on the Debenture described herein notwithstanding, the Holder does not waive interest that may have accrued at a default rate of interest and liquidated damages, if any, that may have accrued on the Debenture through the date of this Allonge, which default interest and liquidated damages, if any, remain outstanding and payable. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 98,600 shares of the Company’s common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY (v) On September 13, 2018, the Company made a second Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the “Allonge”) to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $31,350 ($13,750 – original Principal Amount of the Debenture + $12,100 1 st nd see NOTE F - DERIVATIVE LIABILITY (vi) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. The Eagle Note will mature on one year from the Issue Date. Eagle is to fund the $1,104,000 purchase price of he Eagle Note in tranches. The first tranche of $250,000 was received by the Company on February 13, 2019. (vii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY
Schedule of Pre-payment of Notes Payable Based on Compounding Percentage	The Eagle Note may be pre-paid in whole or in part by paying Eagle the following premiums: PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I)

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	The derivative liability consists of: December 31, 2019 December 31, 2018 Convertible Promissory Note dated May 25, 2017 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information $ - $ 8,385 Warrants issued to EMET in connection with the above Convertible Promissory Note dated May 25, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 72,468 Convertible Promissory Note dated September 14, 2017 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 43,780 Warrants issued to EMET in connection with the above Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 18,150 Convertible Promissory Note dated January 9, 2018 payable to EMET Capital Partners, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 63,680 Allonge dated March 28, 2018 to the Convertible Promissory Note dated September 14, 2017 Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 38,526 Warrants issued to EMET in connection with the above Allonge dated March 28, 2018 to the Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 15,991 Allonge 2 dated September 13, 2018 to the Convertible Promissory Note dated September 14, 2017 Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information - 17,512 Warrants issued to EMET in connection with the above Allonge 2 dated September 13, 2018 to the Convertible Promissory Note dated September 14, 2017. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i) - 1,818 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information 182,625 - Convertible Promissory Notes dated October 18, 2019, payable to EMET. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information 543,240 - Total derivative liability $ 725,865 $ 280,310 (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jan. 04, 2019	Jul. 31, 2018	Mar. 10, 2017	Dec. 31, 2019	Dec. 31, 2018
Number of shares issued	645,129		26,905,969
Estimated economic life of license				5 years
Advertising costs
Derivative liability				725,865	$ 280,310
Cumulative effect of accumulated deficit				108,427
Warrant [Member]
Derivative liability				$ 0	$ 108,427
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation				470,599,900
Green C Corporation [Member] | Former Share Holders [Member]
Percentage of issued and outstanding shares acquired		94.00%
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued		9,411,998
Conversion of convertible preferred stock		50
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.
Green C Corporation [Member] | Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired		100.00%
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 24,662								$ 24,662
Current liabilities	1,599,296								1,599,296
Working capital deficit	1,546,634								1,546,634
Net loss	$ (1,096,037)	$ (126,430)	$ (287,779)	$ (138,349)	$ 24,473	$ (964,322)	$ 22,314	$ 78,465	(1,648,595)	$ (839,070)
Net cash provided in operating activities									$ (285,229)	$ (100,109)

Acquisition of Green C Corpor_3

Acquisition of Green C Corporation (Details Narrative) - Green C Corporation [Member] - USD ($)	Dec. 31, 2019	Jul. 31, 2018
Total liabilities		$ 550,136
Accounts payable and accrued expenses		90,724
Accrued interest		15,813
Loans payable to related parties		$ 89,774
Acquisition Agreement [Member]
Total liabilities	$ 164,841
Accounts payable and accrued expenses	62,500
Accrued interest	12,567
Loans payable to related parties	89,774
Amount of debt forgiven	$ 550,136
Class A Common Stock [Member]
Percentage of ownership acquired		100.00%

Acquisition of Green C Corpor_4

Acquisition of Green C Corporation - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - Green C Corporation [Member]	Jul. 31, 2018USD ($)
Total Assets
Accounts payable and accrued expenses	90,724
Accrued interest	15,813
Loans payable to related parties	89,774
Notes payable to third parties	83,323
Derivative liability	270,502
Total current liabilities and total liabilities	$ 550,136

Loans Payable to Related Part_3

Loans Payable to Related Parties (Details Narrative) - USD ($)	Jul. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Repayment of related party debt			$ 783
Loan and Contribution Agreements [Member] | Maximum [Member]
Repayment of related party debt	$ 1,500,000

Loans Payable to Related Part_4

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total	$ 260,000	$ 260,000
Elisha Kalfa and Yonah Kalfa [Member]
Total	180,000	180,000
Fernando Bisker and Sigalush, LLC [Member]
Total	$ 80,000	$ 80,000

Loans Payable to Related Part_5

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	Dec. 31, 2019	Dec. 31, 2018
Elisha Kalfa and Yonah Kalfa [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666
Fernando Bisker and Sigalush, LLC [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666

Notes Payable to Third Partie_2

Notes Payable to Third Parties (Details Narrative)	Feb. 12, 2019
Eagle Equities, LLC [Member]
Issuance of note, description	Any amount of principal or interest on the Eagle Note, which is not paid when due shall bear interest at the rate of twenty four (24%) per annum from the due date thereof until the same is paid ("Default Interest"). Eagle has the right beginning on the date which is one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the Eagle Note into fully paid and non-assessable shares of common stock of the Company at the conversion price (the "Conversion Price"). The Conversion Price shall be, equal to 65% of the lowest closing price of the Company's common stock as reported on the National Quotations Bureau OTC Market exchange which the Company's shares are traded or any exchange upon which the Common Stock may be traded in the future ("Exchange"), for the fifteen prior trading days including the day upon which a Notice of Conversion is received by the Company. The Eagle Note contains other customary terms found in like instruments for conversion price adjustments.

Notes Payable to Third Partie_3

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) - USD ($)		Dec. 31, 2019	Dec. 31, 2018
Notes payable to third parties, total		$ 399,318	$ 64,914
Convertible Promissory Note One [Member]
Notes payable to third parties, total	[1]		3,469
Convertible Promissory Note Two [Member]
Notes payable to third parties, total	[2]		16,500
Convertible Promissory Note Three [Member]
Notes payable to third parties, total	[3]		23,450
Convertible Promissory Note Four [Member]
Notes payable to third parties, total	[4]	2,420	14,520
Convertible Promissory Note Five [Member]
Notes payable to third parties, total	[5]	1,100	6,600
Promissory Note [Member]
Notes payable to third parties, total		375	375
Convertible Promissory Note Six [Member]
Notes payable to third parties, total	[6]	250,082
Convertible Warrant Note One [Member]
Notes payable to third parties, total	[6]	74,566
Convertible Warrant Notes Two [Member]
Notes payable to third parties, total	[7]	22,823
Convertible Warrant Notes Three [Member]
Notes payable to third parties, total	[7]	20,084
Convertible Warrant Notes Four [Member]
Notes payable to third parties, total	[7]	2,281
Convertible Promissory Note Seven [Member]
Notes payable to third parties, total	[7]	$ 25,587
[1]	On May 25, 2017, the Company executed a Convertible Note (the "Convertible Note") payable to Emet Capital Partners, LLC, ("EMET") in the principal amount of $55,000 in exchange for $50,000 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (May 25, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the "Fixed Conversion Price"); or (ii) 50% multiplied by the Market Price (as defined). "Market Price" means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 440,000 shares of the Company's common stock at an exercise price of $.50 for a term of 5-years. As part of the Convertible Note, the Company executed a Registration Rights Agreement (the "RRA") dated May 25, 2017. Among other things, the RRA provided for the Company to file a Registration Statement with the SEC covering the resale of shares underlying the Convertible Note and the warrant and to have declared effective such Registration Statement. The Registration Statement was declared effective by the Securities and Exchange Commission on August 31, 2017. On September 19, 2018, $32,000 principal of the Convertible Note (and $4,638 accrued interest) was converted into 1,465,523 shares of Company common stock. On October 26, 2018, $30,531 principal of the Convertible Note (and $503 accrued interest) was converted into 1,034,477 shares of Company common stock. On January 4, 2019, $670 principal of the Convertible Note (and $100 accrued interest) was converted into 769,785 shares of Company common stock. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[2]	On September 14, 2017, the Company executed a Convertible Note (the "Convertible Note") payable to Emet Capital Partners, LLC, ("EMET") in the principal amount of $13,750 in exchange for $12,500 cash. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (September 14, 2018) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the "Fixed Conversion Price"); or (ii) 50% multiplied by the Market Price (as defined). "Market Price" means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 110,000 shares of the Company's common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[3]	On January 9, 2018, the Company executed a Convertible Note (the "Convertible Note") payable to Emet Capital Partners, LLC, ("EMET") in the principal amount of $20,000 in exchange for entry into a Waiver Agreement pertaining to the Securities Purchase Agreements entered into between the Parties dated May 25, 2017 and September 14, 2017 along with a Convertible Note issued by the Company on each of the same dates. The Company received $0 cash from issuance of the Convertible Note. The Convertible Note is convertible, in whole or in part, at any time and from time to time before maturity (January 9, 2019) at the option of the holder at the Variable Conversion Price, which shall mean the lesser of (i) $0.25 (the "Fixed Conversion Price"); or (ii) 50% multiplied by the Market Price (as defined). "Market Price" means the lowest Trading Prices (as defined below) for the Common Stock during the twenty (20) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Convertible Note has a term of one (1) year and bears interest at 5% annually (default interest rate 15%). Please see NOTE F - DERIVATIVE LIABILITY for further information.
[4]	On March 28, 2018, the Company made an Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the "Allonge") to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $25,850 ($13,750 - original Principal Amount of the Debenture + $12,100 Allonge). The amendment to the Principal Amount due and owing on the Debenture described herein notwithstanding, the Holder does not waive interest that may have accrued at a default rate of interest and liquidated damages, if any, that may have accrued on the Debenture through the date of this Allonge, which default interest and liquidated damages, if any, remain outstanding and payable. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 98,600 shares of the Company's common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[5]	On September 13, 2018, the Company made a second Allonge to the Convertible Debenture due September 14, 2018 (hereinafter the "Allonge") to Emet Capital Partners, LLC. The Principal Amount as stated on the face of the Debenture shall be increased to $31,350 ($13,750 - original Principal Amount of the Debenture + $12,100 1st Allonge + $5,500 2nd Allonge). The amendment to the Principal Amount due and owing on the Debenture described herein notwithstanding, the Holder does not waive interest that may have accrued at a default rate of interest and liquidated damages, if any, that may have accrued on the Debenture through the date of this Allonge, which default interest and liquidated damages, if any, remain outstanding and payable. As part of the transaction, EMET was also issued a warrant granting the holder the right to purchase up to 11,000 shares of the Company's common stock at an exercise price of $.50 for a term of 5-years. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[6]	On February 12, 2019, (the "Issue Date") the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC ("Eagle"), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the "Eagle Note"). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. The Eagle Note will mature on one year from the Issue Date. Eagle is to fund the $1,104,000 purchase price of he Eagle Note in tranches. The first tranche of $250,000 was received by the Company on February 13, 2019.
[7]	On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC ("Emet"). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY for further information.

Notes Payable to Third Partie_4

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) (Parenthetical)

Dec. 24, 2019USD ($)shares

Dec. 20, 2019USD ($)shares

Nov. 11, 2019USD ($)shares

Oct. 18, 2019USD ($)Integer

Apr. 16, 2019USD ($)shares

Feb. 14, 2019shares

Feb. 13, 2019USD ($)

Feb. 12, 2019USD ($)

Jan. 04, 2019USD ($)shares

Oct. 26, 2018USD ($)shares

Sep. 19, 2018USD ($)shares

Jan. 09, 2018USD ($)Integer$ / shares

Sep. 14, 2017USD ($)Integer$ / sharesshares

May 25, 2017USD ($)Integer$ / sharesshares

Mar. 28, 2017$ / shares

Dec. 31, 2019USD ($)shares

Dec. 31, 2018USD ($)

Sep. 13, 2018USD ($)$ / sharesshares

Mar. 28, 2018USD ($)$ / sharesshares

Number of stock value issued for debt conversion

$ 58,728

$ 58,728

$ 104,901

$ 100,072

$ 100,072

Warrants issued to purchase common stock | shares

1,400

Accrued interest

$ 515

$ 4,035

$ 2,680

$ 7,961

$ 100

Debt conversion converted shares issued | shares

637,273

1,468,204

1,748,363

1,384,600

769,785

1,034,477

1,465,523

2,500,000

Convertible Promissory Note One [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

May 25, 2018

Debt instrument, principal amount

$ 670

$ 30,531

$ 32,000

$ 55,000

Number of stock value issued for debt conversion

$ 50,000

Conversion price | $ / shares

$ 0.25

Trading days percentage

50.00%

Trading days period | Integer

20

Debt instrument, term

1 year

Warrants issued to purchase common stock | shares

440,000

Exercise price of warrants | $ / shares

$ 0.50

Warrant term

5 years

Accrued interest

$ 100

$ 503

$ 4,638

Debt conversion converted shares issued | shares

769,785

1,034,477

1,465,523

Convertible Promissory Note Two [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Sep. 14, 2018

Debt instrument, principal amount

$ 13,750

Number of stock value issued for debt conversion

$ 12,500

Conversion price | $ / shares

$ 0.25

Trading days percentage

50.00%

Trading days period | Integer

20

Debt instrument, term

1 year

Warrants issued to purchase common stock | shares

110,000

Exercise price of warrants | $ / shares

$ 0.50

Warrant term

5 years

Default interest rate

15.00%

Convertible Promissory Note Three [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Jan. 9, 2019

Debt instrument, principal amount

$ 20,000

Conversion price | $ / shares

$ 0.25

Trading days percentage

50.00%

Trading days period | Integer

20

Debt instrument, term

1 year

Default interest rate

15.00%

Unamortized debt discount

$ 0

$ 550

Proceeds from issuance of convertible debt

$ 0

Convertible Promissory Note Four [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Sep. 14, 2018

Debt instrument, principal amount

$ 25,850

Warrants issued to purchase common stock | shares

98,600

Exercise price of warrants | $ / shares

$ 0.50

Warrant term

5 years

Debtenture [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, principal amount

$ 13,750

$ 13,750

Allonge [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, principal amount

$ 12,100

Convertible Promissory Note Five [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Sep. 14, 2018

Debt instrument, principal amount

$ 31,350

Warrants issued to purchase common stock | shares

11,000

Exercise price of warrants | $ / shares

$ 0.50

Warrant term

5 years

First Allonge [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, principal amount

$ 12,100

Second Allonge [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, principal amount

$ 5,500

Promissory Note [Member] | John T. Root [Member]

Debt instrument, interest rate

4.00%

Debt instrument, maturity date

Sep. 28, 2017

Conversion price | $ / shares

$ 0.001

Convertible Promissory Note Six [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Debt instrument, principal amount

$ 1,200,000

Debt instrument, term

1 year

Unamortized debt discount

33,396

0

Debt conversion, original issue discount

$ 96,000

Funding value of issuance of note

$ 1,104,000

Proceeds from issuance of convertible debt

$ 250,000

Convertible Warrant Note One [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Debt conversion converted shares issued | shares

9,000,000

Unamortized debt discount

294,234

0

Convertible Warrant Note One [Member] | Eagle Equities, LLC [Member] | First Exchange Agreement [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Debt instrument, principal amount

$ 20,399

Trading days percentage

75.00%

Trading days period | Integer

15

Accrued interest

$ 5,189

Debt instrument, periodic payment

$ 25,587

Convertible Warrant Note One [Member] | Eagle Equities, LLC [Member] | Second Exchange Agreement [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Trading days percentage

75.00%

Trading days period | Integer

15

Debt instrument, periodic payment

$ 675,000

Convertible Warrant Notes Two [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

90,054

0

Convertible Warrant Notes Three [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

79,248

0

Convertible Warrant Notes Four [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

9,005

0

Convertible Promissory Note Seven [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Unamortized debt discount

$ 0

$ 0

Notes Payable to Third Partie_5

Notes Payable to Third Parties - Schedule of Pre-payment of Notes Payable Based On Compounding Percentage (Details) - Eagle Equities, LLC [Member]	Feb. 13, 2019
Less Than or Equals to 30 Days [Member]
Pre-payment of convertible note percentage	105% * (Principal + Interest ("P+I")
31 - 60 Days [Member]
Pre-payment of convertible note percentage	110% * (P+I)
61 - 90 Days [Member]
Pre-payment of convertible note percentage	115% * (P+I)
91 - 120 Days [Member]
Pre-payment of convertible note percentage	120% * (P+I)
121 - 150 Days [Member]
Pre-payment of convertible note percentage	125% * (P+I)
151 - 180 Days [Member]
Pre-payment of convertible note percentage	130% * (P+I)

Derivative Liability (Details N

Derivative Liability (Details Narrative) - Convertible Promissory Notes [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Fair value of assumption stock price	$ 0.1007	$ 0.1655
Measurement Input, Exercise Price [Member]
Fair value of assumption exercise price		$ 0.0525
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair value of assumption exercise price	0.045
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair value of assumption exercise price	$ 0.0655
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value of assumption term	6 months	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value of assumption term	135 days	6 months
Measurement Input, Price Volatility [Member]
Fair value of assumption expected volatility	130.68%	286.71%
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair value of assumption risk free interest rate	1.83%	2.47%
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair value of assumption risk free interest rate	1.85%	2.50%

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liability (Details) - USD ($)		Dec. 31, 2019	Dec. 31, 2018
Total derivative liability		$ 725,865	$ 280,310
Warrants One [Member]
Total derivative liability	[1]		72,468
Warrants Two [Member]
Total derivative liability	[1]		18,150
Warrants Three [Member]
Total derivative liability	[1]		15,991
Warrants Four [Member]
Total derivative liability	[1]		1,818
Convertible Promissory Notes One [Member]
Total derivative liability			8,385
Convertible Promissory Notes Two [Member]
Total derivative liability			43,780
Convertible Promissory Notes Three [Member]
Total derivative liability			63,680
Convertible Promissory Notes Four [Member]
Total derivative liability			38,526
Convertible Promissory Notes Five [Member]
Total derivative liability			17,512
Convertible Promissory Notes Six [Member]
Total derivative liability		182,625
Convertible Promissory Note Seven [Member]
Total derivative liability		$ 543,240
[1]	As discussed in Note A above, warrants with "down round" features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

Capital Stock and Warrants (Det

Capital Stock and Warrants (Details Narrative)	Dec. 24, 2019USD ($)shares	Dec. 20, 2019USD ($)shares	Nov. 11, 2019USD ($)shares	Oct. 18, 2019USD ($)Integer	Aug. 15, 2019USD ($)shares	May 29, 2019shares	Apr. 16, 2019USD ($)shares	Feb. 14, 2019$ / sharesshares	Jan. 04, 2019USD ($)$ / sharesshares	Oct. 26, 2018USD ($)shares	Sep. 19, 2018USD ($)shares	Jul. 31, 2018shares	Sep. 15, 2017shares	Mar. 22, 2017shares	Mar. 10, 2017shares	Feb. 03, 2017shares	Sep. 30, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)shares	Mar. 31, 2017USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Jun. 13, 2018$ / sharesshares	Mar. 28, 2018$ / sharesshares	Sep. 14, 2017$ / sharesshares	May 25, 2017$ / sharesshares
Number of shares issued during the period, shares									645,129						26,905,969
Number of shares issued for services																						2,000,000
Value of shares issued for services | $																	$ 12,250	$ 75,880
Consulting fees | $																								$ 50,000
Officer compensation | $																						$ 500,000	$ 204,000	185,593
Debt conversion converted shares issued	637,273	1,468,204	1,748,363				1,384,600		769,785	1,034,477	1,465,523												2,500,000
Number of stock value issued for debt conversion | $	$ 58,728	$ 58,728	$ 104,901				$ 100,072		$ 100,072
Accrued interest | $	$ 515	$ 4,035	$ 2,680				$ 7,961		$ 100
Loss on conversion of debt | $																							$ (320,025)	$ (592,907)
Warrants to purchase common stock									1,400
Common Stock [Member]
Number of common stock converted																					1,465,523
Number of shares issued for services																	175,000	542,000
Value of shares issued for services | $																	$ 175	$ 542
Third Party [Member]
Debt conversion converted shares issued													375,000
Two Consulting Firm Entities [Member]
Number of shares issued for services						542,000
Eagle Equities, LLC [Member] | Convertible Warrant Note One [Member]
Debt conversion converted shares issued								9,000,000
Debt instrument, maturity date				Oct. 18, 2020
Debt instrument, interest rate				2.00%
Eagle Equities, LLC [Member] | Convertible Warrant Note One [Member] | First Exchange Agreement [Member]
Accrued interest | $				$ 5,189
Debt instrument, principal amount | $				$ 20,399
Trading days percentage				75.00%
Trading days period | Integer				15
Debt instrument, periodic payment | $				$ 25,587
Debt instrument, maturity date				Feb. 12, 2020
Debt instrument, interest rate				6.00%
Eagle Equities, LLC [Member] | Convertible Warrant Note One [Member] | Second Exchange Agreement [Member]
Trading days percentage				75.00%
Trading days period | Integer				15
Debt instrument, periodic payment | $				$ 675,000
Debt instrument, maturity date				Oct. 18, 2020
Debt instrument, interest rate				2.00%
Wayne Anderson [Member]
Number of shares issued for services																						2,000,000
Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares							1,384,600		695,129
Conversion price | $ / shares									$ 0.001
Number of shares issued for services					175,000
Debt conversion converted shares issued									769,785	1,034,477	1,465,523								769,785
Number of stock value issued for debt conversion | $									$ 670	$ 30,531	$ 32,000
Accrued interest | $							$ 7,961		100	503	4,638
Excess of common stock value | $																		131,537	$ 99,302	$ 82,758	$ 510,149
Fair value of common stock | $					$ 12,250					$ 113,792	$ 546,787							$ 179,998	100,072
Excess of common stock, shares										1,034,479	1,465,523							1,384,600
Loss on conversion of debt | $										$ 31,034	$ 36,638							$ 47,961	$ 770
Warrants to purchase common stock								9,000,000																	11,000	96,800	110,000	440,000
Debt instrument, principal amount | $							$ 40,500		$ 670
Warrant exercise price | $ / shares								$ 0.075	$ 0.001																$ 0.50	$ 0.50	$ 0.50	$ 0.50
Warrant term																									5 years	5 years	5 years	5 years
Number of warrant issued									1,400
Number of warrant outstanding
Sylios Corp [Member]
Ownership percentage															19.99%	80.01%
Number of shares issued during the period, shares															5,378,476	21,527,493
Common stock, shares held																500
Consulting Firm [Member]
Number of shares issued for services														100,000
Consulting fees | $																						$ 25,000
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued during the period, shares												9,411,998
Number of common stock converted												50
Common stock, voting rights												Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.
Series B Convertible Preferred Stock [Member] | Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares								9,000,000
Conversion price | $ / shares								$ 0.075
Preferred stock conversion basis, description								Each share of Series B Convertible Preferred Stock is convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock is less than $0.075 per share.
Green C Corporation [Member] | Class A Common Stock [Member]
Ownership percentage												100.00%
Common stock, voting rights												Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Gross Profit On Product Trans_2

Gross Profit On Product Transactions (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2018	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018
Repayments to supplier				$ 783
Gross profit				$ 86,898
Elisha Kalfa, Green C's CEO[Member]
Gross profit	$ 13,986
NFW Marketing [Member]
Commission received	13,965
Bitcoin Mining Rig Machines [Member] | Green C's Corporation [Member]
Proceeds from machines sold		$ 2,929,000
Bitcoin Mining Rig Machines [Member] | Third Party [Member]
Proceeds from machines sold		1,720,000
Bitcoin Mining Rig Machines [Member] | Focus Global Supply [Member]
Repayments to supplier		4,517,000
Commission paid to third party		59,000
Gross profit		$ 72,912
Telecommunications Parts [Member]
Repayments to supplier	111,127
Proceeds from sale of telecommunications	$ 111,147

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jul. 15, 2019	Jul. 31, 2018	Jun. 26, 2018	Jun. 21, 2018	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Officers compensation					$ 500,000	$ 204,000	$ 185,593
Pharmedica, Ltd. [Member]
Minimum annual royalty amount						50,000
Impairment charge						69,749
Reduction of carrying value of assets						69,749
Intangible assets						0
Exclusive License Agreement [Member] | Green C's Corporation [Member]
License fee				$ 100,000
Annual royalties rate			5.00%
Minimum annual royalty amount			$ 50,000
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Minimum [Member]
Annual royalties rate	10.00%
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Maximum [Member]
Annual royalties rate	17.00%
Royalty payment	$ 1,000,000
Services Agreements [Member]
Officers compensation						$ 204,000	$ 134,593
Services Agreements [Member] | Chief Executive Officer [Member]
Agreement terms		5 years
Officers compensation		$ 10,000
Services Agreements [Member] | Chief Legal Officer [Member]
Officers compensation		$ 7,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 27, 2020	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Jan. 04, 2019	Oct. 26, 2018	Sep. 19, 2018	Mar. 31, 2020	Dec. 31, 2019
Debt conversion converted shares issued		637,273	1,468,204	1,748,363	1,384,600	769,785	1,034,477	1,465,523		2,500,000
Debt conversion of shares, value		$ 58,728	$ 58,728	$ 104,901	$ 100,072	$ 100,072
Subsequent Event [Member]
Debt conversion converted shares issued									21,484,688
Debt principal amount									$ 165,350
Debt interest amount									11,793
Debt conversion of shares, value									406,093
Loss on debt conversion									$ 228,949
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GW Holdings, LLC [Member] | Convertible Redeemable Promissory Note [Member]
Debt instrument, face amount	$ 166,500
Debt instrument, interest rate	6.00%
Debt instrument, maturity date	Jan. 27, 2021
Debt instrument, original issue discount	$ 13,500
Debt instrument, issuance price	$ 153,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Securities purchase agreement, amendment description	An amendment to a Securities Purchase Agreement entered into between the Company and Eagle Equities, LLC on February 12, 2019, was executed on January 27, 2020. A subsequent closing of an additional $150,000 in net proceeds to the Company note occurred on the filing of the Company's resale registration statement covering the $1,200,000 note being purchased. An additional closing of $85,000 in net proceeds to the Company occurred on the effectiveness of such registration statement, provided that the shares registered under the registration statement are sufficient to allow for the full conversion of the funded portion of the Note into registered shares. The Buyer retains the right to purchase the unfunded balance of the $1,200,000 Note (the "Unfunded Balance") until February 12, 2021, provided that each purchase must be in an amount of not less than $100,000. Any rights to purchase a portion of the Unfunded Balance outstanding after 12 months shall be terminated and the Buyer shall have no rights to purchase the Unfunded Balance. The closing of the transactions contemplated by this Agreement (the "Closing") shall occur on the Closing Date at such location as may be agreed to by the parties. In addition, the Company agrees to reserve with its transfer agent, 400% of the discount value of the funded balance of the Note at each closing. All other terms and conditions of the SPA shall remain in full force and effect, unless modified by this Amendment. This amendment shall be governed and construed under the laws of the State of New York, without regard to its conflict of laws provision.
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | Resale Registration Statement [Member]
Debt instrument, face amount	$ 1,200,000
Net proceeds from note	150,000
Debt instrument, unfunded balance	1,200,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | Effectiveness of Registration Statement [Member]
Net proceeds from note	$ 85,000